General Information of Drug Metabolite (DM) (ID: DM000867)
DM Name
Estradiol-17 beta
Synonyms
estradiol|beta-Estradiol|17beta-Estradiol|50-28-2|Oestradiol|Dihydrofolliculin|Estrace|Vivelle|Ovocyclin|progynon|Dihydrotheelin|Dihydroxyestrin|Diogynets|Gynoestryl|Aquadiol|Climara|Diogyn|Gynergon|Vagifem|Dimenformon|Follicyclin|Oestroglandol|Aerodiol|Bardiol|Corpagen|Divigel|Estraderm|Estrovite|Femestral|Ginosedol|Lamdiol|Macrodiol|Oestergon|Ovasterol|Ovastevol|Perlatanol|Primofol|Profoliol|Syndiol|Altrad|Evorel|Dihydromenformon|Estraldine|Estroclim|Estrogel|Menorest|Nordicol|Ovahormon|Femogen|Systen|Zumenon|estradiol-17beta|cis-Estradiol|D-Oestradiol|D-Estradiol|Estraderm TTS|Progynon DH|Climaderm|Compudose|Dermestril|Ovocycline|Trocosone|Estring|Innofem|Oesclim|Alora|Encore|Dihydroxyoestrin|17beta-Oestradiol|Progynon-DH|Estrasorb|Fempatch|Gynestrel|Gynodiol|Microdiol|Oestrogynal|Ovociclina|Ovocylin|Tradelia|Esclim|Macrol|Menest|Zerella|Estroclim 50|Oestradiol R|SK-Estrogens|Estring vaginal ring|Elestrin|Estrifam|Extrasorb|Ginedisc|Estreva|Evamist|Femtran|Trial SAT|Theelin, dihydro-|GynPolar|Compudose 200|Compudose 365|Sandrena Gel|Sisare Gel|Estrofem 2|Estradot|Menostar|Oestrogel|Zesteem|Estrofem Forte|Climara Forte|Profoliol B|Estraderm TTS 50|Oestradiol Berco|Estraderm MX|17b-Oestradiol|VIVELLE-DOT|NSC-9895|Estrapak 50|Oestradiolum|17 beta-Estradiol|Estradiol-17-beta|Estradiolum|Estrodiolum|Gelestra|3,17-Epidihydroxyestratriene|Dihydroxyesterin|cis-Oestradiol|Estrogens, esterified|17.beta.-Estradiol|B-Estradiol|Epiestriol 50|17beta oestradiol|Estra-1,3,5(10)-triene-3,17beta-diol|Oestradiol-17beta|Estradiol Anhydrous|E(sub 2)|17-beta-estradiol|Estradiol-17 beta|Estradiolum [INN]|Estradiolo [DCIT]|Oestradiol-17-beta|Elestrim|Estradiolo|Femanest|Femestrol|Minivelle|Yuvvexy|Estradiol-3,17beta|17-beta-OH-estradiol|3,17-beta-Estradiol|3,17-beta-Oestradiol|3,17-Epidihydroxyoestratriene|D-3,17beta-Estradiol|Sandrena 1|17b-Estradiol|Estraderm (TN)|[3H]-estradiol|17|A-estradiol|17|A-Oestradiol|Estrogel (TN)|Climara (TN)|Divigel (TN)|Estrace (TN)|Estring (TN)|Innofem (TN)|Vagifem (TN)|Vivelle (TN)|C18H24O2|(17beta)-Estra-1,3,5(10)-triene-3,17-diol|17.beta.-Oestradiol|CCRIS 280|Destradiol|Zesteen|17-beta-OH-oestradiol|CHEBI:16469|Estradiol [USAN:INN]|HSDB 3589|3,17.beta.-Estradiol|D-3,17beta-Oestradiol|Estrodiolum [INN-Latin]|D-3,17-beta-Estradiol|D-3,17-beta-Oestradiol|.beta.-Estradiol|(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol|EINECS 200-023-8|.beta.-Oestradiol|Estrasorb (TN)|[3H]]estradiol|NSC-20293|Estradiol 17-beta|17-beta-oestradiol|component of Menrium|UNII-4TI98Z838E|IMVEXXY|TX-004HR|3,17beta-Estradiol|Estradiol, .beta.-|Estradiol-17.beta.|Estra-1,3,5(10)-triene-3,17-diol (17beta)-|Oestradiol-17.beta.|Estraderm TTS 100|17-.beta.-oestradiol|4TI98Z838E|ESTRADIOL HEMIHYDRATE|Oestra-1,3,5(10)-triene-3,17beta-diol|17.beta.-OH-estradiol|17-.BETA.-Estradiol|17.beta.-OH-oestradiol|17beta estradiol (E2)|17beta-Estra-1,3,5(10)-triene-3,17-diol|WC3011|1,3,5-Estratriene-3,17-beta-diol|CHEMBL135|(17beta)-estra-1(10),2,4-triene-3,17-diol|D-3,17.beta.-Estradiol|WC-3011|D-3,17.beta.-Oestradiol|Estradiol [USP:INN:BAN]|3,17beta-Dihydroxyestra-1,3,5-triene|Estra-1,3,5(10)-triene-3,17-diol, (17beta)-|3,17beta-Dihydroxyoestra-1,3,5-triene|3,17-beta-Dihydroxyoestra-1,3,5-triene|MLS000069494|3,17b-Dihydroxyestra-1,3,5(10)-triene|(+)-3,17.beta.-Estradiol|141290-02-0|DTXSID0020573|Estra-1,3,5(10)-triene-3,17-beta-diol|Estradiol valerate metabolite e2|BIJUVA COMPONENT ESTRADIOL|Oestra-1,3,5(10)-triene-3,17-beta-diol|3,17-beta-Dihydroxyestra-1,3,5(10)-triene|NSC9895|3,17-beta-Dihydroxy-1,3,5(10)-oestratriene|ANGELIQ COMPONENT ESTRADIOL|EC 200-023-8|ORIAHNN COMPONENT ESTRADIOL|PREFEST COMPONENT ESTRADIOL|17-beta-Estra-1,3,5(10)-triene-3,17-diol|17beta-Oestra-1,3,5(10)-triene-3,17-diol|17-beta-Oestra-1,3,5(10)-triene-3,17-diol|ACTIVELLA COMPONENT ESTRADIOL|ESTRADIOL COMPONENT OF BIJUVA|COMBIPATCH COMPONENT ESTRADIOL|[3H]E2|CMC_11154|ESTRADIOL COMPONENT OF ANGELIQ|ESTRADIOL COMPONENT OF ORIAHNN|ESTRADIOL COMPONENT OF PREFEST|CLIMARA PRO COMPONENT ESTRADIOL|Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-|(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol|E2|ESTRADIOL COMPONENT OF ACTIVELLA|SL-1100|ESTRADIOL COMPONENT OF COMBIPATCH|NCGC00091544-04|ESTRADIOL COMPONENT OF CLIMARA PRO|SMR000059126|E0025|3,17beta-Dihydroxyestra-1,3,5(10)-triene|E 8875|3,17.beta.-Dihydroxyestra-1,3,5(10)-triene|Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.|Benzogynestry|Estropause|S-21400|Estasorb|(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol|[2,4,6,7-3H]-E2|E 2|DTXCID80573|ESTRADIOL (USP MONOGRAPH)|ESTRADIOL [USP MONOGRAPH]|ESTRADIOL IMPURITY A (IP)|ESTRADIOL IMPURITY A [IP]|.alpha.-Estradiol|17?-Estradiol|Activella (Salt/Mix)|Combipatch (Salt/Mix)|Estradiol-17 alpha|Climara Pro (Salt/Mix)|3,17-.beta.-Oestradiol|ETHINYLESTRADIOL IMPURITY D (EP IMPURITY)|ETHINYLESTRADIOL IMPURITY D [EP IMPURITY]|3,3,5(10)-triene|SR-01000075866|oestrodiol|beta-Oestradiol|delta-Estradiol|dihydro-Theelin|estradiol-|NSC20293|beta -estradiol|alpha-Oestradiol|delta-Oestradiol|Estrogel HBF|1jgl|1lhu|1qkt|1qku|[3H]estradiol|1,3,5-Estratriene-3,17.beta.-diol|CAS-50-28-2|Activella (TN)|Estradiol 17B|Progynova (TN)|Elestrin (TN)|Estrofem (TN)|Menostar (TN)|.alpha.-Oestradiol|Estra-1,3,5(10)-triene-3,17-diol|Prestwick_207|3,17b-Estradiol|Angeliq (TN)|Bio-E-Gel|Fem7|[3H]-Estrogen|17 ?-Estradiol|3,17.beta.-Dihydroxyestra-1,3,5-triene|3,17.beta.-Dihydroxyoestra-1,3,5-triene|EvaMist (TN)|Therapeutic Estradiol|Vivelle-Dot (TN)|Alora (TN)|1,3,5,(10)-Estratrien-3,17.beta.-diol|| cent-ESTRADIOL|Beta-estradiol (E2)|Estra-1,3,5(10)-triene-3,17.beta.-diol|Estraderm TTS (TN)|Oestra-1,3,5(10)-triene-3,17.beta.-diol|2j7x|3,17.beta.-Dihydroxy-1,3,5(10)-estratriene|3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene|3,3,5-triene|[3H]17beta-estradiol|ESTRADIOL [INN]|ESTRADIOL [JAN]|Estradiol acetate (TN)|(17?)-Estra-1,3,5(10)-triene-3,17-diol|17.beta.-Estra-1,3,5(10)-triene-3,17-diol|ESTRADIOL [MI]|Estrasorb Topical (TN)|ESTRADIOL [HSDB]|ESTRADIOL [INCI]|Estradiol valerate (TN)|17.beta.-Oestra-1,3,5(10)-triene-3,17-diol|Opera_ID_1688|Prestwick0_000441|Prestwick1_000441|Prestwick2_000441|Prestwick3_000441|Spectrum5_002055|17beta-estradiol (E2)|ESTRADIOL [VANDF]|Estradiol cypionate (TN)|3,17beta-Dihydroxy-1,3,5(10)-estratriene|alpha-estradiol (obsolete)|beta-Estradiol, >=98%|bmse000642|D08QMX|Epitope ID:136018|(+)-3,17b-Estradiol|ESTRADIOL [USP-RS]|ESTRADIOL [WHO-DD]|SCHEMBL8049|(+)-3,17beta-Estradiol|Estradiol (JAN/USP/INN)|Tritiated estradiol-17-beta|BIDD:PXR0065|Lopac0_000503|BSPBio_000482|BSPBio_001065|KBioGR_000405|KBioGR_002269|KBioSS_000405|KBioSS_002270|MLS000758312|MLS001076331|MLS001424022|BIDD:ER0125|SPBio_002421|ESTRADIOL [GREEN BOOK]|BPBio1_000532|GTPL1012|GTPL1013|ESTRADIOL [ORANGE BOOK]|NIOSH/KG7030000|UNII-125DP6010H|BDBM17292|KBio2_000405|KBio2_002269|KBio2_002973|KBio2_004837|KBio2_005541|KBio2_007405|KBio3_000769|KBio3_000770|KBio3_002749|1a52|1g50|2d06|cMAP_000005|Bio1_000403|Bio1_000892|Bio1_001381|Bio2_000363|Bio2_000843|HMS1362E07|HMS1569I04|HMS1792E07|HMS1990E07|HMS2051C17|HMS2090E18|HMS2096I04|HMS2236H04|HMS3261F07|HMS3403E07|HMS3713I04|HMS3884A08|beta-Estradiol, analytical standard|(8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol|BCP08579|ESTRADIOL 17-BETA [VANDF]|HY-B0141|Tox21_111148|Tox21_202057|Tox21_300288|Tox21_500503|1,5-Estratriene-3,17.beta.-diol|HB2494|LMST02010001|LS-137|s1709|Estradiol-17-beta-6,7-(sup 3)H|[2,4,6,7-3H]-17beta-estradiol|AKOS015896570|CCG-100808|CS-1938|CS-O-11584|DB00783|LP00503|NC00058|SDCCGSBI-0050487.P002|IDI1_002118|SMP1_000121|1,3,5(10)-estratriene-3,17b-diol|NCGC00091544-00|NCGC00091544-01|NCGC00091544-02|NCGC00091544-05|NCGC00091544-06|NCGC00091544-07|NCGC00091544-09|NCGC00091544-10|NCGC00091544-11|NCGC00091544-12|NCGC00091544-13|NCGC00091544-14|NCGC00091544-15|NCGC00091544-16|NCGC00091544-18|NCGC00091544-27|NCGC00179321-01|NCGC00179321-02|NCGC00254177-01|NCGC00259606-01|NCGC00261188-01|17-E|AC-22346|AS-13729|CPD000059126|Estra-1,3,5(10)-triene-3,17b-diol|Oestra-1,3,5(10)-triene-3,17b-diol|WLN: L E5 B666TTT&J E1 FQ OQ|Estra-1,5(10)-triene-3,17.beta.-diol|Estradiol, meets USP testing specifications|3,17beta-dihydroxyestra-1,3,5(10)-trien|Estra-1,3,5(10)-triene -3,17beta-diol|EU-0100503|KG70300000|Oestra-1,5(10)-triene-3,17.beta.-diol|3,17-dihydroxy-delta(1,3,5-10)-estratriene|C00951|D00105|EN300-119518|(17b)-Estra-1,3,5(10)-triene-3,17-diol|13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol|17.beta.-Estra-1,5(10)-triene-3,17-diol|17.beta.-Oestra-1,5(10)-triene-3,17-diol|17-beta-Estradiol 100 microg/mL in Acetonitrile|Q422416|SR-01000721892|13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol|Estra-1,3,5(10)-triene-3,7-diol(17.beta.)-|Estra-1,3,5(10)-trieno-3,17-diol (17?)-|Estra-1,5(10)-triene-3,17-diol (17.beta.)-|ESTRADIOL BENZOATE IMPURITY A [EP IMPURITY]|ESTRADIOL VALERATE IMPURITY A [EP IMPURITY]|Q-201503|SR-01000075866-1|SR-01000075866-4|SR-01000721892-3|BRD-K18910433-001-04-4|BRD-K18910433-001-43-2|estra-1(10),2,4-triene-3,17-diol, (17beta)-|Estra-1,5(10)-triene-3,17-diol, (17.beta.)-|Estra-1,3,5(10)-triene-3,17-diol, (17.beta.)-|Z1521553843|B8B5AEF5-4957-49EB-A14F-444A8212C482|beta-Estradiol, BioReagent, powder, suitable for cell culture|Estradiol, United States Pharmacopeia (USP) Reference Standard|13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,17.BETA.-OL|beta-Estradiol, powder, gamma-irradiated, suitable for cell culture|Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-|Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material|(13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol|(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol|(1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]hepta
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 272.4 Topological Polar Surface Area 40.5
Heavy Atom Count 20 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
PubChem CID
5757
Complexity
382
Formula
C18H24O2
Canonical SMILES
CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
InChIKey
VOXZDWNPVJITMN-ZBRFXRBCSA-N
IUPAC name
(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Toxicity Properties of This DM
Documented Toxicity Properties
Toxicity Class Unreported
Predicted Toxicity Properties
Physical and chemical properties LogP

The log of the n-octanol/water distribution coefficient.

LogP possess a leading position with considerable impact on both membrane permeability and hydrophobic binding to macromolecules. Therefore, LogP is widely used in drug discovery and development as an indicator of potential utility of a solute as a drug.

The predicted logP of a compound in the range from 0 to 3 log mol/L will be considered proper.

4.108 TPSA

Topological polar surface area

In TPSA, PSA is estimated only from the syntype (topology) of atoms in the molecule, without considering the three-dimensional structure of the molecule, which is the origin of the name topological polar surface area.

The TPSA of a compound in the range from 0 to 140 will be considered proper, based on Veber rule.

40.46
Pfizer Rule: Rejected

Molecules with a high log P (>3) and low TPSA (<75) are likely to be toxic.

Pfizer infered the relationship between the physicochemical properties and toxicity of the drug from an animal tolerability (IVT) study dataset of 245 preclinical Pfizer compounds.Compounds with a high log P (>3) and low TPSA ( <75) are likely to be toxic.

(Bioorg Med Chem Lett. 18(17):4872-5. 2008)

Structural Characteristics ALARM NMR Rule

Molecules containing the reactivity-related thiol substructures are likely to be toxic.

The high-throughput screening (HTS) hit rate of reactive compounds was evaluated by NMR screening, X-ray crystallography and other biochemical and biophysical experiments, and then 75 thiol substructures for predicting reactivity were obtained by computational means for 2348 screening hit reactive compounds and 1156 reactive compounds obtained by La protein experiments.The molecule was matched to 75 reactivity-related substructures to obtain the information how many alarm groups the molecule contained and determine whether it was a thiol-reactive compound. Molecules with the thiol substructures are likely to be toxic.

(J Am Chem Soc. 127(1):217-24. 2005)

0 PAINS

Molecules containing the reactive substructures are likely to be toxic.

Pan Assay Interference Compounds (PAINS) is one of the most famous frequent hitters filters, which comprises 480 substructures derived from the analysis of FHs determined by six target-based HTS assay. By application of these filters, it is easier to screen false positive hits and to flag suspicious compounds in screening databases. One of the most authoritative medicine magazines Journal of Medicinal Chemistry even requires authors to provide the screening results with the PAINS alerts of active compounds when submitting manuscripts.

(J Med Chem. 45(1):137-42. 2002)

0
BMS Rule

Molecules containing the reactivity-related substructures are likely to be toxic.

BMS's primary HTS data over the past 12 years was evaluated and analyzed to determine the correlation of a group of compound functional groups with Promiscuity, defined as a drug that acts with multiple molecular targets and exhibits different pharmacological effects.

(J Chem Inf Model. 46(3):1060-8. 2006)

0 Chelator Rule

Molecules containing the substructures associated with metalloprotease targeting are likely to be toxic.

The chelate substructure fragment library (eCFL) for targeting metalloproteinases was prepared and its effectiveness in screening metalloproteinase inhibitors was verified by analysis and fluorescence-based assay experiments, and 55 substructures associated with metalloprotease targeting were finally determined as alert structures.

(ChemMedChem. 5(2):195-9. 2010)

0
Genotoxic Carcinogenicity Rule

Molecules containing the Genotoxic substructures are likely to be carcinogenic.

By constructing a molecular structure dataset containing the corresponding Ames test data (mutagens and non-mutagens). The substructure of the dataset is searched, and then the toxic substructure obtained by using chemical and mechanical knowledge and statistical criteria is derived, and the new toxic substructure is obtained and approved, and finally the reliability of the verification set is verified. Molecules containing these substructures may cause carcinogenicity or mutagenicity through genotoxic mechanisms.There are 117 substructures in this endpoint.

(J Med Chem. 48(1):312-20. 2005)

0 Non-genotoxic Carcinogenicity Rule

Molecules containing the NonGenotoxic substructures are likely to be carcinogenic.

Through the analysis and verification of the existing molecular library or the molecular library mined by data, the list of non-gene carcinogenic substructures (SA) is obtained according to the computerized data mining analysis, and finally the reliability of the substructure is verified. Molecules containing these substructures may cause carcinogenicity through nongenotoxic mechanisms. There are 23 substructures in this endpoint.

(Mutat Res. 659(3):248-61. 2008)

0
Toxicity Model Prediction hERG Blockers

The possibility of causing cardiotoxicity.

The human ether-a-go-go related gene. The During cardiac depolarization and repolarization, a voltage-gated potassium channel encoded by hERG plays a major role in the regulation of the exchange of cardiac action potential and resting potential. The hERG blockade may cause long QT syndrome (LQTS), arrhythmia, and Torsade de Pointes (TdP), which lead to palpitations, fainting, or even sudden death.So build a model by collecting a dataset to predict whether a compound is a hERG Blocker.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.558 (+) H-HT

The possibility of causing .hepatotoxicity.

The human hepatotoxicity. Drug induced liver injury is of great concern for patient safety and a major cause for drug withdrawal from the market. Adverse hepatic effects in clinical trials often lead to a late and costly termination of drug development programs.So build a model by collecting datasets to predict whether compounds will cause hepatotoxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.278 (--)
DILI

The possibility of causing liver injury.

Drug-induced liver injury (DILI) has become the most common safety problem of drug withdrawal from the market over the past 50 years.So build a model by collecting datasets to predict whether compounds will cause liver injury.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.222 (--) CAMES Toxicity

The possibility of causing mutagenicity.

The Ames test for mutagenicity. The mutagenic effect has a close relationship with the carcinogenicity, and it is the most widely used assay for testing the mutagenicity of compounds.So build a model by collecting datasets to predict whether compounds will cause mutagenicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.029 (---)
Carcinogencity

The possibility of causing Carcinogencity.

Among various toxicological endpoints of chemical substances, carcinogenicity is of great concern because of its serious effects on human health. The carcinogenic mechanism of chemicals may be due to their ability to damage the genome or disrupt cellular metabolic processes. Many approved drugs have been identified as carcinogens in humans or animals and have been withdrawn from the market.So build a model by collecting datasets to predict whether compounds will cause Carcinogencity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.734 (++) Respiratory Toxicity

The possibility of causing Respiratory Toxicity.

Among these safety issues, respiratory toxicity has become the main cause of drug withdrawal. Drug-induced respiratory toxicity is usually underdiagnosed because it may not have distinct early signs or symptoms in common medications and can occur with significant morbidity and mortality.Therefore, careful surveillance and treatment of respiratory toxicity is of great importance.So build a model by collecting datasets to predict whether compounds will cause Respiratory Toxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.967 (+++)
Full List of Drug-Metabolizing Enzyme (DME) Related to This DM
DME(s) Producing This DM through Metabolism
DME Name DME ID Reactant Reaction Related Drug REF
Aromatase (CYP19A1) DME0002 Unclear - Unclear Dehydroepiandrosterone [1]
DME(s) Metabolizing This DM
DME Name DME ID Product Reaction Related Drug REF
Aromatase (CYP19A1) DME0002 Unclear - Unclear Dehydroepiandrosterone [1]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - 2-Hydroxylation Estradiol acetate [2] , [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - Hydroxylation Estradiol acetate [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - Hydroxylation Estradiol cypionate [2] , [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - 2-Hydroxylation Estradiol cypionate [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - Hydroxylation Estradiol valerate [2] , [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Oxidation - 2-Hydroxylation Estradiol valerate [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - 2-Hydroxylation Estradiol acetate [2] , [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - Hydroxylation Estradiol acetate [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - Hydroxylation Estradiol cypionate [2] , [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - 2-Hydroxylation Estradiol cypionate [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - Hydroxylation Estradiol valerate [2] , [3]
Cytochrome P450 1A2 (CYP1A2) DME0003 Oxidation - 2-Hydroxylation Estradiol valerate [3]
Cytochrome P450 1B1 (CYP1B1) DME0023 Oxidation - 4-Hydroxylation Estradiol acetate [2]
Cytochrome P450 1B1 (CYP1B1) DME0023 Oxidation - 4-Hydroxylation Estradiol cypionate [2]
Cytochrome P450 1B1 (CYP1B1) DME0023 Oxidation - 4-Hydroxylation Estradiol valerate [2]
Cytochrome P450 1B1 (CYP1B1) DME0023 Unclear - Unclear Estradiol acetate [3]
Cytochrome P450 1B1 (CYP1B1) DME0023 Oxidation - Hydroxylation Estradiol cypionate [3]
Cytochrome P450 1B1 (CYP1B1) DME0023 Oxidation - Hydroxylation Estradiol valerate [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - 2-Hydroxylation Estradiol acetate [2] , [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - Hydroxylation Estradiol acetate [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - Hydroxylation Estradiol cypionate [2] , [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - 2-Hydroxylation Estradiol cypionate [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - Hydroxylation Estradiol valerate [2] , [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Oxidation - 2-Hydroxylation Estradiol valerate [3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Unclear - Unclear Dehydroepiandrosterone [1]
Cytochrome P450 3A5 (CYP3A5) DME0012 Oxidation - 4-Hydroxylation Estradiol acetate [2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Oxidation - 4-Hydroxylation Estradiol cypionate [2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Oxidation - 4-Hydroxylation Estradiol valerate [2]
Estradiol 17-beta-dehydrogenase 1 (HSD17B1) DME0420 Unclear - Unclear Estradiol acetate [4]
Estradiol 17-beta-dehydrogenase 1 (HSD17B1) DME0420 Unclear - Unclear Estradiol cypionate [4]
Estradiol 17-beta-dehydrogenase 1 (HSD17B1) DME0420 Unclear - Unclear Estradiol valerate [4]
Sulfotransferase (SULT) DMEN061 Unclear - Unclear Dehydroepiandrosterone [1]
Sulfotransferase (SULT) DMEN061 Unclear - Unclear Dehydroepiandrosterone [1]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2] , [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol cypionate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2] , [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Unclear - Unclear Estradiol valerate [2]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol acetate [6]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol acetate [2]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol acetate [2]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol acetate [2]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol acetate [2]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol cypionate [7]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol cypionate [6]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol valerate [7]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Estradiol valerate [6]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Dehydroepiandrosterone [1]
UDP-glucuronyltransferase (UGT) DMEN064 Unclear - Unclear Dehydroepiandrosterone [1]
⏷ Show the Full List of DM
Full List of Drug(s) That Produce This DM By Metabolism
Estradiol acetate DR0636 Approved Acquired prion disease
Estradiol cypionate DR0638 Approved Acquired prion disease
Estradiol valerate DR0644 Approved Acquired prion disease
Dehydroepiandrosterone DR0431 Approved Dyspareunia
Estramustine DR0645 Approved Prostate cancer
Estrone sulfate DR0650 Investigative Discovery agent
References
1 Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model: Impact on Cellular Proliferation Front Pharmacol. 2018 Jul 10;9:742. doi: 10.3389/fphar.2018.00742.
2 The metabolism of estradiol; oral compared to intravenous administration J Steroid Biochem. 1985 Dec;23(6A):1065-70. doi: 10.1016/0022-4731(85)90068-8.
3 Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
4 Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24.
5 Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry Anal Chem. 2009 Dec 15;81(24):10143-8. doi: 10.1021/ac9019126.
6 FooDB:Estradiol acetate
7 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.